Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 18/9/2019
SIETES contiene 92806 citas

 
 
 1 a 20 de 670 siguiente >>
Presentar resultados
Seleccionar todas
1.Enlace a cita original Cita con resumen
Anónimo. Towards better patient care: drugs to avoid in 2019. Prescrire Int 2019;39:abril. [Ref.ID 103075]
2.Enlace a cita original Cita con resumen
Chapman KR, Hurst JR, Frent SM, Larbiq M, Fogel R, Guerin T, Banerji D, Patalano F, Goyal P, Pfister P, Kostikas K, Wedzicha JA. Long-term triple therapy de-escalation to indacaterol/glycopyrronium in patients with chronic obstructive pulmonary disease (SUNSET): a randomized, double-blind, triple-dummy clinical trial. Am J Respir Crit Care Med 2018;198:1 de agosto. [Ref.ID 102826]
4.Enlace a cita original Cita con resumen
Vozoris NT, Wang X, Austin PC, O'Donnell DE, Aaron SD, To TM, Gershon AS. Incident diuretic drug use and adverse respiratory events among older adults with chronic obstructive pulmonary disease . Br J Clin Pharmacol 2018;84:marzo. [Ref.ID 102651]
5. Cita con resumen
González AV, Coulombe J, Ernst P, Suissa S. Long-term use of inhaled corticosteroids in COPD and the risk of fracture. Chest 2018;153:321-8. [Ref.ID 102538]
6.Enlace a cita original Cita con resumen
Wang M-T, Liou J-T, Lin CW, Tsai C-L, Wang Y-H, Hsu Y-J, Lai J-H. Association of cardiovascular risk with inhaled long-acting bronchodilators in patients with chronic obstructive pulmonary disease. A nested case-control study. JAMA Intern Med 2018;178:febrero. [Ref.ID 102529]
7. Cita con resumen
Wilke RA, Freeman JW. Potential health implications related to fracking. JAMA 2017;318:1645-6. [Ref.ID 102135]
8. Cita con resumen
Anónimo. EMA panel recommends approval of GSK’s triple inhaler to treat COPD. DIA Daily 2017:2. [Ref.ID 102050]
9.Enlace a cita original Cita con resumen
Anónimo. Indacaterol for chronic obstructive pulmonary disease. Therapeutics Letter 2016:1-2. [Ref.ID 101043]
11. Cita con resumen
McEvoy RD, Antic NA, Heeley E, Luo Y, Ou Q, Zhang X, Mediano O, Chen R, Drager LF, Liu Z, Chen G, Du B, McArdle N, Mukherjee S, Tripathi M, Billot L, Li Q, Lorenzi-Filho G, Barbe F, Redline S, Wang J, Arima H, Neal B, White DP, Grunstein RR, Zhong N, Anderson CS, SAVE Investigators and Coordinators. CPAP for prevention of cardiovascular events in obstructive sleep apnea. N Engl J Med 2016;375:919-31. [Ref.ID 100743]
12.Tiene citas relacionadas Cita con resumen
Bhatt DL, Mehta C. Adaptive designs for clinical trials. N Engl J Med 2016;375:65-74. [Ref.ID 100614]
13. Cita con resumen
Anónimo. Uméclidinium et BPCO. Prescrire 2016;36:488-9. [Ref.ID 100547]
14.Tiene citas relacionadas
Donohue JF. Another choice for prevention of COPD exacerbations. N Engl J Med 2016;374:2284-6. [Ref.ID 100406]
15.Tiene citas relacionadas Cita con resumen
Wedzicha JA, Banerji D, Chapman KR, Vestbo J, Roche N, Ayers RT, Thach C, Fogel R, Patalano F, Vogelmeier CF. Indacaterol–glycopyrronium versus salmeterol–fluticasone for COPD. N Engl J Med 2016;374:2222-34. [Ref.ID 100405]
16.Enlace a cita original Cita con resumen
Kirchmayer U, Cascini S, Agabiti N, Di Martino M, Bauleo L, Formoso G, Voci C, Pistelli R, Patorno E, Davoli M, on behalf of the OUTPUL study group. One-year mortality associated with COPD treatment: a comparison of tiotropium and long-acting beta2-agonists in three Italian regions: results from the OUTPUL study. Pharmacoepidemiol Drug Saf 2016;25:578-89. [Ref.ID 100264]
17.Tiene citas relacionadas Cita con resumen
Vestbo J, Anderson JA, Brook RD, Calverley PMA, Celli BR, Crim C, Martínez F, Yates J, Newby DE, SUMMIT Investigators. Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a double-blind randomised controlled trial. Lancet 2016;387:1817-26. [Ref.ID 100248]
18.Tiene citas relacionadas Cita con resumen
Brussele G. Vilanterol fluticasone and mortality in comorbid COPD GOLD B. Lancet 2016;387:1791-2. [Ref.ID 100246]
20.Enlace a cita original Cita con resumen
Anónimo. Revisión sobre el riesgo de neumonía asociado a la administración de corticoides inhalados para el tratamiento de la EPOC . Agencia Española de Medicamentos y Productos Sanitarios (AEMPS) 2016:1. [Ref.ID 100075]
Seleccionar todas
 
 1 a 20 de 670 siguiente >>